4887-24-5Relevant articles and documents
Preparation method of moxifloxacin hydrochloride chelate
-
Paragraph 0021; 0027-0032, (2021/03/05)
The invention provides a preparation method of moxifloxacin hydrochloride chelate, and belongs to the technical field of heterocyclic compound preparation. The preparation method comprises the following steps: keeping excessive acetic acid, adding trimethyl borate into the acetic acid, and reacting at 110-120 DEG C; after the reaction is finished, cooling, adding gatifloxacin intermediate, heatingto 110-120 DEG C after the addition is finished, keeping on reacting; recovering the fraction under reduced pressure until the reaction is finished, and recovering the solvent until the solvent is dry to obtain the chelate. The method has the advantages of simple process, economy, environmental friendliness and high product purity.
Preparation method of moxifloxacin hydrochloride
-
Paragraph 0018-0028; 0031-0041; 0044-0054, (2019/08/30)
The invention discloses a preparation method of moxifloxacin hydrochloride. The method comprises the following steps: performing condensation by using 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-ethylquinolinecarboxylate as a central ring, and (S,S)-2,8-diazabicyclo[4,3,0]nonane as a side chain, after alkali hydrolysis is completed, adding a part of 6N hydrochloric acid, performing primary crystallization, adding the remaining 6N hydrochloric acid, performing secondary crystallization, and performing recrystallization on the crystallized product obtain by the secondary crystallization once by using ethanol to obtain the moxifloxacin hydrochloride with a high content and excellent quality. When the method provided by the invention is adopted to prepare the moxifloxacin hydrochloride, product loss caused by repeated crystallization is reduced, labor intensity is reduced, energy consumption is reduced, product stability is improved, product quality is greatly improved, and themethod is suitable for industrialized large-scale production; and the prepared moxifloxacin hydrochloride contains 99.6%-102.0% of C21H25ClFN3O4 calculated by an anhydrate, and has a low total impurity content.
SOLID PHARMACEUTICAL COMPOSITION
-
Paragraph 0103-0110, (2016/04/09)
[Problem] To provide a novel pharmaceutical composition which contains a medically active component and which can suppress delays in the release of said component due to gelling. [Solution] This solid pharmaceutical composition contains a compound represented by general formula (1), or a salt thereof, a cellulosic excipient, and a salting-out agent.